Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12845363 | 0.87 | CDK2 (0.52) | CDK2KMT2APTGS2HTR2AHTR1A | |
| SCHEMBL12811043 | 0.87 | KMT2A (0.54) | CDK2ALDH1A1KMT2AMEN1PTGS2 | |
| SCHEMBL12845777 | 0.87 | HTR1A (0.55) | CDK2KMT2AMEN1PTGS2HTR2A | |
| SCHEMBL8030584 | 0.86 | CDK2 (0.50) | CDK2ALDH1A1KMT2APTGS2HTR2A | |
| SCHEMBL8041023 | 0.85 | KMT2A (0.53) | CDK2ALDH1A1KMT2AMEN1PTGS2 | |
| Serdemetan SCHEMBL29375950 | 0.85 | HRH3 (0.58) | ALDH1A1KMT2AMEN1PTGS2HTR2A | |
| Serdemetan SCHEMBL3012498 | 0.85 | HRH3 (0.58) | ALDH1A1KMT2AMEN1PTGS2HTR2A | |
| SCHEMBL12845509 | 0.85 | MEN1 (0.49) | CDK2ALDH1A1KMT2AMEN1HTR2A | |
| SCHEMBL19114665 | 0.82 | HTR2A (0.34) | CDK2ALDH1A1KMT2AMEN1PTGS2 | |
| SCHEMBL12845775 | 0.81 | CDK2 (0.46) | CDK2KMT2AHTR2AHTR1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393801-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2185541-B1 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-28 | — | — | EP | disclosed |
| US-8853406-B2 | Substituted phenylenediamines as inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-07 | — | — | US | disclosed |
| US-8541442-B2 | Indole derivatives as anticancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8404683-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICAL N.V. (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | Janssen Pharmaceutica NV a corporation | 2011-12-01 | — | — | US | disclosed |
| US-20110130418-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN-CILAG (FR) | 2011-06-02 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | LACRAMPE JEAN FERNAND ARMAND | 2011-03-03 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| US-7834016-B2 | Inhibitors of the interaction between MDM2 and p53 | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-16 | — | — | US | disclosed |
| WO-2010089327-A2 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2009019274-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-02-12 | — | — | WO | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130418-A1 | SUBSTITUTED PHENYLENEDIAMINES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | CDK2 21/4885ALDH1A1 718/4885KMT2A 3082/4885 |
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | IDO1, IDO2, INMT | CDK2 114/4885ALDH1A1 299/4885KMT2A 1513/4885 |
| US-20110053937-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | CDK2 36/4885ALDH1A1 4018/4885KMT2A 2688/4885 |
| US-20080039472-A1 | Inhibitors of the Interaction Between Mdm2 and P53 | TP53, MDM2, TP53BP1 | CDK2 36/4885ALDH1A1 4018/4885KMT2A 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.